A-47 | P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes

Amit Sachdeva,Shiyun Zhu,Ratnabhushan Mutyala,Neha Mantri,Edward J Mcnulty,Matthew D Solomon

doi:10.1016/j.jscai.2022.100102

A-47 | P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes

Amit Sachdeva, Shiyun Zhu + Show 4 more

Open Access

https://doi.org/10.1016/j.jscai.2022.100102

Copy DOI

Journal: Journal of the Society for Cardiovascular Angiography & Interventions	Publication Date: May 1, 2022
Citations: 1	License type: cc-by-nc-nd

Affiliation: Kaiser Permanente, Drexel University, Stanford University

#P2Y12 Inhibitor #Inhibitors In Acute Coronary Syndromes + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Current guidelines recommend a novel P2Y12 inhibitor in patients with ACS, but clinical benefit in the community remains controversial. Our objective was to compare the safety and efficacy of clopidogrel to ticagrelor and prasugrel in patients with ACS undergoing PCI in a real-world population

Full Text